Skip to content

Evaluation of dietary intervention models for management of stage I hypertensive patients in a primary care setting: randomized controlled clinical trial

The effectiveness of Dietary Approaches to Stop Hypertension (DASH) counselling on cardiovascular risk among patients with newly diagnosed grade 1 hypertension: a randomised clinical trial

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-13003014
Enrollment
Unknown
Registered
2013-01-22
Start date
2013-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

Two groups:Health Education

Sponsors

Health and Health Services Research Fund, Food and Health Bureau, Hong Kong
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) aged between 40 to 70 years; (2) newly diagnosed as having stage one hypertension (SBP 140-159 and/or 90-99 mmHg) as defined by the seventh report of the Joint National Committee based on the results of blood pressure readings in two separate clinic visits; (3) currently not on any antihypertensive medications.

Exclusion criteria

Exclusion criteria: - Unwillingness or inability to modify current diet; - Alcoholic beverage intake > 14 drinks/week; - Use of food supplements that cannot be discontinued; - Current use of antihypertensive drugs or blood pressure-modifying medications that cannot be discontinued; - Cardiovascular disease event within the past 6 months; - Body mass index > 35 kg/m2; - Impaired fasting glucose or diabetes; - History of hypercalcemia or hyperkalemia; - Renal insufficiency; - Active malignancy or cancer therapy within the past 6 months; - Anemia; - Inflammatory bowel disease, malabsorption, hepatitis; - Asthma; - Gout; - Other chronic disease thought to interfere with the effect of the diet or with participation; - Use of antacids containing magnesium or calcium, insulin, oral corticosteroids, lithium, unstable doses of psychotropics, bile acid sequestering resins, oral antiasthmatics, digitalis, or phenytoin; - Dyslipidemia (Total cholesterol > 6.2 mmol/l, Triglyceride > 2.3 mmol/l, LDL-cholesterol: > 4.0 mmol/l); - Poor compliance during screening.

Design outcomes

Primary

MeasureTime frame
Change in BP and CV risk;

Secondary

MeasureTime frame
BMI and lipid profiles;Factors associated with non-optimisation of CV risk;

Countries

China

Contacts

Public ContactWONG Chi Sang, Martin
wong_martin@cuhk.edu.hk+852 22528782

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 12, 2026